Compounders Research Compare

Genprex, Inc.(GNPX)

Biotechnology · Austin, TX

$2.69-0.03 (-1.10%)

Delayed quote: Oct 6, 2026, 2:41 PM EDT

About Genprex, Inc.

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Austin, TX

13 employees

www.genprex.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ryan Confer

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T18:46:37.076Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:46:37.076Z.

Quote observation: 2026-10-06T18:41:42.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,358,275
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 15,154,203
TTM operating EBITDA · period ending 2026-06-30: -15,842,711

FMP input reference: 325841a12d79c3b22e4488d0564adef7d4bfa7ba78e5cc1d4c3dcb4b1cd6f762

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GNPX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

GNPX Competitors' EV/EBITDA Ratio

Genprex, Inc.

Current

Market Cap

$1.36M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Artelo Biosciences, Inc.

Market Cap

$1.34M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NewcelX Ltd.

Market Cap

$1.37M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Jupiter Neurosciences, Inc.

Market Cap

$1.33M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INVO Fertility, Inc.

Market Cap

$1.42M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NEXGEL, Inc.

Market Cap

$1.44M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Curis, Inc.

Market Cap

$1.47M

EV/EBITDA Ratio

N/A

TTM Avg

341.73x

3Y Avg

341.73x

5Y Avg

341.73x

PMGC Holdings Inc.

Market Cap

$1.47M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lakewood-Amedex Biotherapeutics, Inc.

Market Cap

$1.49M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Propanc Biopharma, Inc.

Market Cap

$1.14M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Genprex, Inc. (GNPX)	$1.36M	N/A	N/A	N/A	N/A
Artelo Biosciences, Inc. (ARTL)vs ›	$1.34M	N/A	N/A	N/A	N/A
NewcelX Ltd. (NCEL)vs ›	$1.37M	N/A	N/A	N/A	N/A
Jupiter Neurosciences, Inc. (JUNS)vs ›	$1.33M	N/A	N/A	N/A	N/A
INVO Fertility, Inc. (IVF)vs ›	$1.42M	N/A	N/A	N/A	N/A
NEXGEL, Inc. (NXGL)vs ›	$1.44M	N/A	N/A	N/A	N/A
Curis, Inc. (CRIS)vs ›	$1.47M	N/A	341.73x	341.73x	341.73x
PMGC Holdings Inc. (ELAB)vs ›	$1.47M	N/A	N/A	N/A	N/A
Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs ›	$1.49M	N/A	N/A	N/A	N/A
Propanc Biopharma, Inc. (PPCB)vs ›	$1.14M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics